139 related articles for article (PubMed ID: 1531213)
1. Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.
Sebolt-Leopold JS; Vincent PW; Beningo KA; Elliott WL; Leopold WR; Heffner TG; Wiley JN; Stier MA; Suto MJ
Int J Radiat Oncol Biol Phys; 1992; 22(3):549-51. PubMed ID: 1531213
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic transforming potential of nitroimidazole radiosensitizers.
Hall EJ; Hei TK
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
[TBL] [Abstract][Full Text] [Related]
3. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
Cole S; Stratford IJ; Bowler J; Nolan J; Wright EG; Lorimore SA; Adams GE
Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):387-95. PubMed ID: 2061115
[TBL] [Abstract][Full Text] [Related]
4. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
Cole S; Stratford IJ; Fielden EM; Adams GE; Leopold W; Elliott W; Suto M; Sebolt-Leopold J
Int J Radiat Oncol Biol Phys; 1992; 22(3):545-8. PubMed ID: 1735694
[TBL] [Abstract][Full Text] [Related]
5. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
Cole S; Stratford IJ; Adams GE; Fielden EM; Jenkins TC
Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
[TBL] [Abstract][Full Text] [Related]
6. In vitro assessment of the oncogenic potential of nitroimidazole radiosensitizers.
Hei TK; Geard CR; Osmak RS; Hall EJ
Int J Radiat Oncol Biol Phys; 1985 Sep; 11(9):1653-8. PubMed ID: 3839777
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger M; Workman P
Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
[TBL] [Abstract][Full Text] [Related]
8. Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).
Campora E; Vidili G; Oliva C; Ardizzoni A; Rosso R
Oncology; 1991; 48(5):403-5. PubMed ID: 1836058
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
Walton MI; Workman P
Cancer Chemother Pharmacol; 1988; 22(4):275-81. PubMed ID: 3168141
[TBL] [Abstract][Full Text] [Related]
10. Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo.
Ahmed I; Jenkins TC; Walling JM; Stratford IJ; Sheldon PW; Adams GE; Fielden EM
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1079-81. PubMed ID: 3755711
[TBL] [Abstract][Full Text] [Related]
11. Studies with bifunctional bioreductive drugs. I. In vitro oncogenic transforming potential.
Hei TK; He ZY; Piao CQ; Hall EJ
Radiat Res; 1990 Oct; 124(1 Suppl):S44-9. PubMed ID: 2236509
[TBL] [Abstract][Full Text] [Related]
12. Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069.
Walling J; Stratford IJ; Adams GE; Stephens MA
Int J Radiat Biol Relat Stud Phys Chem Med; 1988 Apr; 53(4):641-9. PubMed ID: 3258298
[TBL] [Abstract][Full Text] [Related]
13. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
Kenward H; Elliott J; Lee T; Pelligand L
BMC Vet Res; 2017 Aug; 13(1):244. PubMed ID: 28814338
[TBL] [Abstract][Full Text] [Related]
14. Phase II trials of ondansetron with high-dose cisplatin.
Kris MG
Semin Oncol; 1992 Aug; 19(4 Suppl 10):23-7. PubMed ID: 1387247
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069.
Workman P; Walton MI
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1307-10. PubMed ID: 6547936
[TBL] [Abstract][Full Text] [Related]
16. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
[TBL] [Abstract][Full Text] [Related]
17. Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analogues.
Walling JM; Stratford IJ; Adams GE; Silver AR; Ahmed I; Jenkins TC; Fielden EM
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1083-6. PubMed ID: 3755712
[TBL] [Abstract][Full Text] [Related]
18. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Gandara DR; Harvey WH; Monaghan GG; Perez EA; Stokes C; Bryson JC; Finn AL; Hesketh PJ
Semin Oncol; 1992 Aug; 19(4 Suppl 10):67-71. PubMed ID: 1387253
[TBL] [Abstract][Full Text] [Related]
19. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
20. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
Jeremić B
Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
